Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

DNA-Guided heart therapy could prevent thousands of heart attacks

NCT ID NCT03783351

Disease control Sponsor: Beijing Anzhen Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether using a person's genetic information to choose their blood thinner medication after getting a heart stent can reduce the risk of heart attacks, strokes, and death. About 4,000 people with heart disease were given either clopidogrel or ticagrelor based on their CYP2C19 gene type. The goal was to see if this personalized approach is safer and more effective than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

4,009 people

The number who actually took part.

Started

May 2019

Expected to finish

Apr 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient ≥18 years of age * Patient presents with acute coronary syndrome (ACS) or stable coronary artery disease (SCAD) * Patient has a percutaneous coronary intervention (PCI) indication and the new generation drug eluting stent(s) is successfully implanted Exclusion Criteria: * Patient unable to receive 12 months of dual anti-platelet therapy * Patient developing procedure-related complications such as stent thrombosis, coronary dissection, coronary perforation, cardiac tamponade or no-reflow during PCI * Contraindicated or allergic to clopidogrel or ticagrelor * Patient or physician refusal to enroll in the study * Patient having received thrombolytic therapy within the previous 24 hours * Physician has known the patient's CYP2C19 genotype * Anticipated discontinuation of dual anti-platelet therapy within the 12-month follow-up period, example for elective surgery * History of intracranial hemorrhage * Patient has a history of bleeding diathesis or coagulopathy * Patient has an active pathological bleeding, such as active gastrointestinal (GI) bleeding * Patient is pregnant, breastfeeding, or planning to become pregnant within 12 months * Patient is receiving chronic oral anticoagulation therapy (i.e., vitamin K antagonist, direct thrombin inhibitor, Factor Xa inhibitor) * Patient with cardiogenic shock or mechanical circulatory assist devices placed * Patient with LVEF \<30% * Patient with active liver diseases * Patient with severe renal insufficiency (eGFR \<30ml/min/1.73m2 based on simplified MDRD equation or CrCl \<30ml/min based on Cockcroft-Gault equation) * Patient has a malignancy or a life expectancy of less than one year * Platelet count \<100 000/μL, or hematocrit \<32% or \>52%, or white blood cell count \<3000/μL

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome Angina, Stable coronary artery disorder intermediate coronary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute coronary syndrome Angina (stable) Drug-eluting stents Genotype

Contacts and locations

Locations

  • Beijing Anzhen Hospital

    Beijing, Beijing Municipality, 100029, China

  • Beijing Chaoyang Hospital

    Beijing, Beijing Municipality, 100000, China

  • Beijing Friendship Hospital

    Beijing, Beijing Municipality, 100050, China

  • Beijing LuHe Hospital

    Beijing, Beijing Municipality, 101199, China

  • Beijing Tong Ren Hospital

    Beijing, Beijing Municipality, 100730, China

  • Beijing Tsinghua Changgung Hospital

    Beijing, Beijing Municipality, 102218, China

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, China

  • Fuwai Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, 100037, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, 100032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.